Weight Loss Injections Are Only Half the Story: How GLP-1 & GIP Medications Really Affect Your Body

Photo by Total Shape on Unsplash

If you are currently taking a weight loss medication like Wegovy®, Ozempic®, Mounjaro® or similar, you’re not alone.

These weight loss injections are transforming the way we approach obesity and metabolic health, with millions of people worldwide now using them.

But as a Functional Medicine Practitioner and Nutritional Therapist, I see the other side every single week in clinic:

• People whose appetite has plummeted so much that they’re barely eating.
• People who are losing weight on the scales… but also losing muscle, energy, and bone mass.
• People who feel anxious about what happens after the injections stop.

The truth is: the medication is powerful, but it’s only half the story.

How you eat, move, sleep and support your organs during treatment will largely determine whether your results are sustainable, and how well you feel along the way.

This is exactly why I created my 7 module group program: to provide the “wraparound care” (especially nutrition and lifestyle support) that NICE and the NHS now recommend for people on these medications.

In this first blog, I want to walk you through what’s actually happening in your body while on weight loss injections, and why a thoughtful plan around them is so important.

What GLP-1 & GIP Medications Are Really Doing Inside You

Every time you eat, your gut releases small messenger hormones called incretins: mainly GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).

These hormones help regulate appetite, satiety, insulin release, and blood sugar balance. However, in some people these signals are not effective enough.

Weight loss injections work by mimicking these hormones but in a much stronger, longer acting way. To give you an example: natural GLP-1 is broken down within minutes, while the medication form stays active for days.

So, what does that mean in practical terms?

Most people experience:

• Feeling full sooner and for longer
• Less interest in food / food “noise” quietening down
• Reduced cravings, especially for ultra processed and sugary foods
• Improved blood sugar control

On the surface this is brilliant, but these shifts can have knock on effects elsewhere.

The Hidden Costs of Eating Less

On these medications, calorie intake often drops by 15–35% or more without people even realising.

This can certainly support weight loss, but your body doesn’t just lose fat.

Without proper support, you may also lose:

• Muscle mass: essential for metabolism, strength, energy, and blood sugar control. Studies show that 25–39% of total weight lost can come from lean mass, not fat.
• Bone density: especially important for women in peri- and post-menopause, as rapid weight loss accelerates bone loss.
• Key micronutrients: because every mouthful now matters, and low intake of iron, zinc, magnesium, calcium, vitamins A, D, E, K, B12 and others is common when appetite drops.

I also see changes in:

• Hydration and digestion: slower gut motility can contribute to constipation, bloating, reflux, or reduced thirst
• Hair, skin and nails: often a sign of low protein or nutrient intake
• Energy and mood: when blood sugar, sleep and nutrient intake become unbalanced

This is not to scare you; these are normal adaptations if the only thing that changes is “less food”.

The good news is that with the right nutrition and lifestyle support, you can protect your muscles, bones, liver, gut and hormones while the medication does its job.

This is exactly what we focus on inside my program.

Toxin Mobilisation: The Part No One Mentions

One piece that often gets missed in standard care is what happens to stored chemicals during fat loss.

Our fat cells are not just cosy storage for excess calories. Over time they can accumulate fat soluble compounds such as environmental chemicals, pollutants, hormone like substances and metabolic by products.

When you start losing fat more rapidly, as many do on these medications, these compounds can be released back into circulation.

Your body is designed to handle this via your:

• Liver
• Gut
• Kidneys
• Skin

But if those systems are already under pressure, you may temporarily feel:

• More tired
• Headachy
• Foggy
• Prone to skin flare ups

This is why, from a functional medicine perspective, I’m so passionate about:

• Supporting bowel regularity
• Keeping hydration optimal
• Prioritising colourful, antioxidant rich foods
• Protecting liver and gallbladder function

In my group program we dedicate an entire module to liver, gallbladder and detox support during fat loss, because “just losing weight” is not the end of the story.

How you lose it matters.

Common Side Effects, And Why You Should Not Ignore Them

The most common symptoms people tell me about when starting or increasing their dose are:

• Nausea
• Constipation, bloating, or excess wind
• Reflux or heartburn
• Fatigue or dizziness
• Hair thinning or brittle nails

These are widely reported in clinical trials of semaglutide and tirzepatide.

Many of these are manageable with simple but strategic nutrition and lifestyle tweaks (which we go step by-step through in the program).

However, it’s also important to say this clearly:

If your symptoms do not feel right, are getting worse, or include severe pain, jaundice, persistent vomiting, or pale/greasy stools, please speak to your prescribing clinician or GP promptly.

More serious side effects like gallbladder issues or pancreatitis are uncommon but documented, and they need medical supervision.

My role is not to replace your prescriber; it is to support your body so you can stay as well and resilient as possible during treatment.

Why “Wraparound Care” Matters More Than Ever

NICE and the NHS now recommend that anyone taking these medications should receive multidisciplinary support, including nutrition and lifestyle guidance.

Why? Because while the medication helps initiate weight loss, your habits determine whether:

• Your muscle and bone mass are preserved
• Your liver and gut cope well with fat loss and toxin mobilisation
• Side effects are minimised
• You avoid nutrient deficiencies
• And most importantly… whether the weight stays off once the injections stop

This is the gap my 7-module group program is designed to fill.

We cover:

• How these medications affect your body (so you feel informed and in control)
• How to nourish yourself when appetite is low
• Practical strategies for digestion, constipation, reflux and loose stools
• Supporting liver, gallbladder and detox pathways
• Sleep, circadian rhythm, stress, emotional eating, and movement

In Part 2 of this blog series, I will be sharing some of the key pillars I use with clients to help them feel well on weight-loss medications: from building a “high-impact” plate when you are only eating a little, to protecting your sleep, stress response and muscle mass.

But if you are already thinking that you would love some structured support with this, then you are very welcome to join the program using this link.

Until next time.

References:

1. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025 May 30. doi: 10.1002/oby.24336. Epub ahead of print. PMID: 40445127.

2. J.P.H. Wilding, R.L. Batterham, S. Calanna, M. Davies, L.F. Van Gaal, I. Lingvay, B.M. McGowan, J. Rosenstock, M.T.D. Tran, T.A. Wadden, et al., Once-weekly semaglutide in adults with overweight or obesity, N Engl J Med 384 (11) (2021) 989–1002.

3. A.M. Jastreboff, L.J. Aronne, N.N. Ahmad, S. Wharton, L. Connery, B. Alves, A. Kiyosue, S. Zhang, B. Liu, M.C. Bunck, et al., Tirzepatide once weekly for the treatment of obesity, N Engl J Med 387 (3) (2022) 205–216.

4. D. Rubino, N. Abrahamsson, M. Davies, D. Hesse, F.L. Greenway, C. Jensen, et al., Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial, JAMA 325 (14) (2021) 1414 1425.

5. J.P.H. Wilding, R.L. Batterham, M. Davies, L.F. Van Gaal, K. Kandler, K. Konakli, I. Lingvay, B.M. McGowan, T.K. Oral, J. Rosenstock, et al., Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, Diabetes Obes Metab 24 (8)(2022) 1553–1564.

6. Christensen, S. Robinson, K, Thomas, S. Williams, D.R. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: a narrative review and discussion of research needs, Obes Pillars 11 (2024) 100121.

7. Prado, Carla M et al. Muscle matters: the effects of medically induced weight loss on skeletal muscle. The Lancet Diabetes & Endocrinology, 2024 Volume 12, Issue 11, 785 – 787. https://pubmed.ncbi.nlm.nih.gov/39265590/

8. Conte C, Hall KD, Klein S. Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant? JAMA. 2024;332(1):9–10. doi:10.1001/jama.2024.6586

9. Cava E, Yeat NC, Mittendorfer B. Preserving Healthy Muscle during Weight Loss. Adv Nutr. 2017 May 15;8(3):511-519. doi: 10.3945/an.116.014506. PMID: 28507015; PMCID: PMC5421125.

10. McCarthy D, Berg A. Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss. Nutrients. 2021 Jul 20;13(7):2473. doi: 10.3390/nu13072473. PMID: 34371981; PMCID: PMC8308821.

11. Chavez AM, Carrasco Barria R, León-Sanz M. Nutrition support whilst on glucagon-like peptide 1 based therapy. Is it necessary? Curr Opin Clin Nutr Metab Care. 2025 Jul 1;28(4):351-357. doi: 10.1097/MCO.0000000000001130. Epub 2025 May 2. PMID: 40401903.

12. Memel Z, Gold SL, Pearlman M, Muratore A, Martindale R. Impact of GLP- 1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia. Curr Nutr Rep. 2025 Apr 28;14(1):63. doi: 10.1007/s13668-025-00649-w. PMID: 40289060.

13. Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab (Seoul). 2019 Sep;34(3):247-262. doi: 10.3803/EnM.2019.34.3.247. PMID: 31565876; PMCID: PMC6769337.

14. SA Shapses, CS Riedt, Bone, body weight, and weight reduction: what are the concerns? J Nutr 136 (6) (2006) 1453–1456, https://doi.org/10.1093/jn/ 136.6.1453.

15. Labouesse MA, Gertz ER, Piccolo BD, et al. Associations among endocrine, inflammatory, and bone markers, body composition and weight loss induced bone loss. Bone. 2014;64:138 –146).